Our most recent update of CLAD+LDAC+Ven now published - almost 200 pts with ~3yr f/u ; CR rate 84% and 92% in TP53 wildtype. @alexbataller onlinelibrary.wiley.com/doi/10.1002/aj…
Tapan Kadia
@TapKadia
Tapan Kadia, MD
- Leukemia Doc at MD Anderson Cancer Center
Leukemia, clinical/translational research. Views, posts and opinions shared are my own.
- Leukemia Doc at MD Anderson Cancer Center
Leukemia, clinical/translational research. Views, posts and opinions shared are my own.
219 Following 3.8K Followers 4.7K Posts
Latest posts 5
Great presentation by @jenweiying summarizing the frontline data with Oral Dac Ven Revumenib in patients with newly diagnosed NPM1-m and KMT2a-r AML. #ASH2025 @MDAndersonNews
Beautiful presentation by Dr. Alexandre Bazinet in the AML oral session for upfront therapy:
Clad/ldac/ven; CRc rate of 86% and 2-yr os of 62%
Clad/ldac/ven; CRc rate of 86% and 2-yr os of 62%
A gentleman and a scholar…
👉👉👉Nice to spend a few moments with our trusted friend & dear colleague Dr Charlie Lu today @MDAndersonNews at the intersection of thoracic/H&N oncology & leukemia ! @doctorpemm @karenluMD @TapKadia #endcancer | @PatrickHwuMD @HemeReports @MpncoD @DavidHongMD @LaurenByersMDView quoted post on X
Abishek Maiti from @MDAndersonNews presenting at the #EHA2024 Late breaking abstract plenary session.
